Chronic Diseases 5 -: Prevention of chronic diseases:: a call to action
Chronic Diseases 5 -: Prevention of chronic diseases:: a call to action
复制标题
DOI：
10.1016/s0140-6736(07)61700-0
复制
发表时间：
2007-12-01
期刊：
影响因子：
168.9
通讯作者：
Leeder, Steve
中科院分区：
文献类型：
--
作者：
Beaglehole, Robert;Ebrahim, Shah;Leeder, Steve
慢性（非传染性）疾病——主要是心血管疾病、癌症、慢性呼吸系统疾病和糖尿病——是导致死亡和残疾的主要原因，但令人惊讶的是，它们是全球卫生议程中被忽视的因素。它们被低估为发展问题，被低估为具有深远经济影响的疾病。实现预防和控制慢性病的全球目标，到2015年将避免3 600万人死亡，并将产生重大的经济效益。实现这一全球目标的主要挑战是证明可以以具有成本效益的方式利用现有的干预措施来实现这一目标。《柳叶刀》上的这一系列论文提供了证据，表明这一目标不仅是可能的，而且是现实的，只需针对高危人群和个人进行少量干预。23个低收入和中等收入国家每年的干预费用总额约为58亿美元（截至2005年）。在本系列的最后一篇论文中，我们呼吁在普遍加强卫生系统的背景下，在全球范围内认真和持续地努力预防和控制慢性病。世卫组织、世界侧翼、区域银行和发展机构、基金会、国家政府、民间社会非政府组织、包括制药业在内的私营部门和学术界需要采取紧急行动。我们设立了慢性病行动小组，以鼓励、支持和监测采取行动，落实循证努力，促进全球、区域和国家采取行动，预防和控制慢性病。
Chronic (non-communicable) diseases-principally cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes-are leading causes of death and disability but are surprisingly neglected elements of the global-health agenda. They are underappreciated as development issues and underestimated as diseases with profound economic effects. Achievement of the global goal for prevention and control of chronic diseases would avert 36 million deaths by 2015 and would have major economic benefits. The main challenge for achievement of the global goal is to show that it can be reached in a cost-effective manner with existing interventions. This series of papers in The Lancet provides evidence that this goal is not only possible but also realistic with a small set of interventions directed towards whole populations and individuals who are at high risk. The total yearly cost of the interventions in 23 low-income and middle-income countries is about US$5.8 billion (as of 2005). In this final paper in the Series we call for a serious and sustained worldwide effort to prevent and control chronic diseases in the context of a general strengthening of health systems. Urgent action is needed by WHO, the World flank, regional banks and development agencies, foundations, national governments, civil society non-governmental organisations, the private sector including the pharmaceutical industry, and academics. We have established the Chronic Disease Action Group to encourage, support, and monitor action on the implementation of evidence-based efforts to promote global, regional, and national action to prevent and control chronic diseases.